Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Ruvometinib Tablets (FCN-159 Tablets) in Pediatric Participants With Neurofibromatosis Type 1

NCT07024394 is registered in ClinicalTrials.gov with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor.

NCT NCT07024394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07024394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Ruvometinib Tablets (FCN-159 Tablets) in Pediatric Participants With Neurofibromatosis Type 1
Lead sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 12, 2025
Completion date
September 23, 2029
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis 1, nf1, plexiform neurofibroma